Trevogrumab

Trevogrumab (INN;[1] development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia.

Trevogrumab
Monoclonal antibody
Type?
SourceHuman
Targetgrowth differentiation factor 8
Clinical data
Other namesREGN1033
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6374H9884N1696O2018S46
Molar mass144037.80 g·mol−1

This drug was developed by Regeneron Pharmaceuticals, Inc.[2]

References
  1. World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Trevogrumab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.